Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer

Dayyani, Farshid; Uhlig, Steffen; Colson, Bertrand; Simon, Kirsten; Rolny, Vinzent; Morgenstern, David; Schlumbrecht, Matthew

doi:10.1097/igc.0000000000000804

Cited by 62 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 CA-125 as a standalone screening test is relatively insensitive for ovarian cancer, finding only about 60% of women with ovarian cancer. 30 Other serum biomarkers such as human epididymis protein (HE4) and human chorionic gonadotropin (HCG) have been tested in combination with CA-125 to improve performance characteristics of serum biomarker screening for ovarian cancer as standalone serum screening tests, 29,31 though evidence suggests that CA-125 is the most robust biomarker of the group. 32 …”

Section: When It Is Not So Simple To Screen: Ovarian Cancermentioning

confidence: 99%

“…26,33 The UK trial tested a proprietary algorithm named ROCA ® that adjusted the biomarker level cut-off for normal results based on women’s clinical characteristics and the TV ultrasound result. 31 The promotion of ROCA ® (Abcodia, Cambridgeshire, UK) serum testing with TV ultrasound ran afoul of the Food and Drug Administration (FDA) for the claim that the ROCA ® test detects ovarian cancer early and reduced mortality. In late 2016 FDA issued a warning against using commercial screening tests for ovarian cancer, saying that, especially for women at high risk for hereditary ovarian cancer, “women and their doctors may not take appropriate actions to reduce their future risk if they rely on a result that shows no cancer currently present.” 34 FDA further stipulated that they did not recommend the use of ovarian cancer screening tests in the general population.…”

Section: When It Is Not So Simple To Screen: Ovarian Cancermentioning

confidence: 99%

See 1 more Smart Citation

Cancer Screening and Early Detection in the 21 st Century

Loud¹,

Murphy²

2017

Seminars in Oncology Nursing

193

123

View full text Add to dashboard Cite

Objective To review the trends in and principles of cancer screening and early detection. Data Sources Journal articles, United States Preventive Services Task Force (U SPSTF) publications, professional organization position statements, evidence-based summaries Conclusion Cancer screening has contributed to decreasing the morbidity and mortality of cancer. Efforts to improve the selection of candidates for cancer screening, to understand the biological basis of carcinogenesis, and the development of new technologies for cancer screening will allow for improvements in the cancer screening over time. Implications for Nursing Practice Nurses are well-positioned to lead the implementation of cancer screening recommendations in the 21st Century through their practice, research, educational efforts and advocacy.

show abstract

Section: When It Is Not So Simple To Screen: Ovarian Cancermentioning

confidence: 99%

Section: When It Is Not So Simple To Screen: Ovarian Cancermentioning

confidence: 99%

Cancer Screening and Early Detection in the 21 st Century

Loud¹,

Murphy²

2017

Seminars in Oncology Nursing

193

123

View full text Add to dashboard Cite

show abstract

“…For instance, in September 2011, the FDA approved human epididymis protein 4 (HE4) as a biomarker for monitoring patients with epithelial OVCA . A “Risk of Ovarian Malignancy Algorithm” (ROMA) utilizing combined serum measurements of HE4 and CA125 demonstrated increased sensitivity in diagnosing OVCA, particularly in the early‐stage patient group . The Tainsky laboratory has also defined specific paraneoplastic autoantibodies as potential markers for initial diagnosis and recurrent disease …”

Section: Discussionmentioning

confidence: 99%

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

et al. 2019

View full text Add to dashboard Cite

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA‐125 and sFR.

show abstract

“…However, CA-125 detection is poorly performed in the diagnosis of patients with early ovarian cancer [5]. The study has reported that the sensitivity and speci city of CA125 are 0.796 and 0.825 [6]. Although HE4 has greater speci city than CA125, the sensitivity has a varying result [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Hou

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer is the most fatal gynecologic malignancy worldwide due to its vagueness, delay in diagnosis, recurrence, and drug resistance. Therefore, a new type of ovarian cancer treatment prediction biomarker is urgently needed to supplement existing tools. A total of 230 people participated in this study. Out of this figure, 100 participants were patients who underwent an ovarian tumor operation, another 100 participants were ovarian benign patients, and the remaining 30 participants were healthy women. Cancer (experimental) group were 100 patients who underwent ovarian tumor operation, while the control groups were 130 participants consisting of 100 ovarian benign patients and 30 healthy women. Levels of SAA, carbohydrate antigen-125 (CA-125), and human epididymis protein 4 (HE4) were assessed using standard laboratory protocols. A total of 5 ovarian cancer tissues and paracancerous tissues were collected and then stored at − 80℃ until the qRT-PCR assay was conducted. Results: The ROC curve of SAA concentration in ovarian cancer was plotted to obtain the area under the curve AUC = 0.889, the cut-off value 17.05 mg/L, the sensitivity 78.4% and specificity 86.5%. Compared with pretreatment, the level of serum SAA decreased significantly after treatment. The results revealed that there was a significant correlation between the level of serum SAA and advanced FIGO stage, histology subtype, lymphatic invasion, and distant metastasis (p = 0.003,0.002,0.000 and 0.001). The quantitative Reverse transcription polymerase chain reaction (qRT-PCR) assay revealed that the Messenger RNA (mRNA) of SAA-1 and SAA-4 was much higher in cancer tissues than in adjacent tissues, and MMPs was up-regulation including MMP-1, MMP-9 and MMP- 12 in OVCAR-3 cell stimulated by SAA. The transwell assay revealed that SAA could promote OVCAR-3 cell migration. Moreover, SAA can regulate EMT markers and promote AKT pathway activation. Conclusions: In summary, our results demonstrated that SAA may be a potential diagnosis and treatment prediction biomarker. The SAA promotes OVCAR-3 cell migration by regulating MMPs and EMT which may correlate with AKT pathway activation.

show abstract

Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer

Abstract: The results presented support the use of ROMA to improve clinical decision making, most notably in patients with early OC.

Cited by 62 publications

References 29 publications

Cancer Screening and Early Detection in the 21 st Century

Cancer Screening and Early Detection in the 21 st Century

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Contact Info

Product

Resources

About